AI agents can play a range of roles, from acting as intelligent collaborators alongside people to independently executing entire workflows. Rooted in the principles of agentic AI, they excel at reasoning through problems, self-directing activities, and adapting to evolving contexts. Whether deployed to support individuals or to autonomously carry out operational tasks, agents enhance productivity, decision-making, and overall efficiency across a broad spectrum of use cases.

Agent Studio reimagines the clinical trial lifecycle, automating slow, manual processes, removing barriers in the clinical process, andintroducing new ways to achieve clinical goals like never before. This first-of-its-kind, AI-powered, no-code platform lets you deployready-to-go agents trained as clinical development experts or create bespoke ones using your own data and expertise, unlockingendless possibilities.

According to ClinicalTrials.gov, there are 3,046 multi-country trials being conducted this year. While many trials remain localized within a single country, there has been a definitive movement towards conducting trials in multiple countries, especially for larger, later-stage trials. This is driven by the positives that multi-country trials offer, like faster patient recruitment, lower costs in some regions, and the need for diverse patient populations.. However, behind the scenes, a critical bottleneck has been slowing many trials down. This bottleneck is the translation process that’s required to make trials work across multiple languages, locales, and regulatory bodies/organizations.

‍